Recruiting
Phase 4

Veligrotug

Sponsor:

Viridian Therapeutics, Inc.

Code:

NCT07832136

Conditions

Thyroid Eye Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

veligrotrug (LUMVOA™)

Study Details

Brief summary:

This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but subsequently had a disease recurrence.

Conditions

Thyroid Eye Disease

Study ID

NCT07832136

Start date

Oct 19, 2026

Status verified date

Nov, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Apr, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Must have a diagnosis of TED with associated signs and symptoms.
  • Must have completed an initial full course of treatment (8 infusions over approximately 21 weeks) with teprotumumab ≥9 months prior to screening.
  • Must have a documented clinical response to teprotumumab.
  • Must have evidence of recurrence following the completion of prior teprotumumab treatment course, as measured by exophthalmometer in the study eye.
  • Must have a Clinical Activity Score (CAS) ≥3 in the study eye.
  • Must not require immediate orbital surgery in the study eye during the anticipated duration of the trial.
  • Must agree to use highly effective contraception as specified in the protocol.
  • Female TED participants must have a negative serum pregnancy test at screening.

Key Exclusion Criteria:

  • Must not have sight-threatening TED (eg, dysthyroid optic neuropathy).
  • Must not have received IGF-1R inhibitor therapy within 9 months prior to screening or received any IGF-1R inhibitor other than teprotumumab at any time.
  • Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to the first dose.
  • Must not have received other immunosuppressive drugs for any condition, including TED, within 12 weeks prior to the first dose or any other therapy for TED (except for artificial tears) within 8 weeks prior to the first dose.
  • Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose.
  • Must not have previous orbital irradiation or decompression surgery for TED to the study eye's orbit.
  • Must not have a pre-existing ophthalmic condition in the study eye which, in the study doctor's opinion, would interfere with interpretation of trial results.
  • Must not have abnormal hearing test before first dose or any history of hearing impairment. Must not also have any history of ear conditions considered significant by the study doctor.
  • Must not have a history of inflammatory bowel disease.
  • Female participants must not be pregnant or breastfeeding.

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: 5 IV infusions of 10 mg/kg of veligrotug

Participants will receive veligrotug10 mg/kg as an intravenous (IV) infusion every 3 weeks (Q3W) for 12 weeks.

Interventions

veligrotrug (LUMVOA™)

intravenous infusions

Primary outcome measure

  • Safety and tolerability of veligrotrug (LUMVOA™) [ Time Frame: Through Week 15 ]

Central Contacts and Locations

Central contacts

Locations

Office of Dr. Amy Patel Jain, MD

Recruiting

Newport Beach, California, United States, 92660

Contacts

Sarasota Retina Institute

Recruiting

Sarasota, Florida, United States, 34239

Contacts

Ophthalmic Consultants of Boston

Recruiting

East Weymouth, Massachusetts, United States, 02189

Contacts

The Center for Eye and Facial Plastic Surgery

Recruiting

Somerset, New Jersey, United States, 08873

Contacts

Neuro-Eye Clinical Trials

Recruiting

Houston, Texas, United States, 34239

Contacts

More Information

Sponsor

Viridian Therapeutics, Inc.

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Keywords

  • TED
  • Thyroid Eye Disease
  • Graves
  • Dysthyroid Ophthalmopathy
  • Graves Eye Disease
  • Graves Orbitopathy
  • Myopathic Ophthalmopathy
  • Thyroid-Associated Ophthalmopathy
  • Edematous Ophthalmopathy
  • Infiltrative Ophthalmopathy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Viridian Therapeutics, Inc. on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.